Relapsed Follicular Lymphoma Recruiting Phase 2 Trials for Idelalisib (DB09054)

IndicationStatusPhase
DBCOND0041364 (Relapsed Follicular Lymphoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04699461Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular LymphomaTreatment